You are here:

apixaban (Eliquis)

Advice

following a full submission

apixaban (Eliquis®) is  accepted for use within NHS Scotland.

Indication under review: treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE in adults.

One phase III study showed non-inferiority of apixaban versus standard anticoagulant therapy including a low molecular weight heparin in combination with a vitamin K antagonist for treatment of DVT/PE. In a 12 month phase III study apixaban demonstrated superiority versus placebo for the prevention of recurrent DVT/PE.

Drug Details

Drug Name: apixaban (Eliquis)
SMC Drug ID: 1029/15
Manufacturer: Pfizer/Bristol Myers Squbb
Indication: Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE in adults.
BNF Category:
Sub Category: 2.8 Anticoagulants and protamine
Submission Type: Full submission
Status: Accepted
Date Advice Published: 9 March 2015

Back